United Nations Office on Drugs and Crimes Background Guide

2026-2027

Cleveland Council on WORLD AFFAIRS

United Nations Office on Drugs and Crime (UNODC) Background Guide

Written by: Marie Chuparkoff, *University of Virginia*

Written August 2026

The United Nations Office on Drugs and Crime (UNODC) is the principal international body responsible for addressing issues such as illicit drug trade, transnational organized crime, corruption, terrorism, and how these issues threaten international security and stability. In 1997, the UN Drug Control Programme and the Centre for International Crime Prevention merged to form the UNODC, and since then, the office has worked with all 193 Member States of the UN to counter the global drug problem, combat transnational crime, and economic corruption, and strengthen global justice systems.

The UNODC follows guidelines and norms set by several international legal instruments, including the UN Convention against Transnational Organized Crime (Palermo Convention), the UN Convention against Corruption (UNCAC), and three international drug control conventions. Through the UNODC and these conventions, Member States cooperate to prosecute organized criminal groups (OCGs), strengthen criminal justice systems, and prevent illicit activities such as drug trafficking and money laundering.[1]

Topic I: Influence of Technological Advancements in the Pharmaceutical Industry

Statement of the Issue:

Technological advancements, from the expansion of the Internet to the integration of artificial intelligence (AI), have influenced the pharmaceutical industry both negatively and positively. With the implementation of digital innovations, the pharmaceutical industry, which refers to the sector of business devoted to the design, development, and production of medications and vaccines, has become a more interconnected and efficient system while facing criminal organizations' exploitation of those innovations.[2] Digital technologies have already

[1] UNODC. "UNODC: About Us," UN Office on Drugs and Crime. Accessed August 17, 2026. https://www.unodc.org/unodc/en/about-unodc/index.html.

[2] NIH. "Pharmaceutical Industry." National Institute of Health. Accessed August 18, 2026. https://toolkit.ncats.nih.gov/glossary/pharmaceutical-industry/.

reduced expenses and enhanced service delivery. While pharmacy services have typically been founded on face-to-face communication and paper-based procedures, digital transformation has optimized the effectiveness, transparency, and quality of care in the industry.[3]

Despite these benefits, digitization of the pharmacy market has created vulnerabilities that can be exploited by illicit actors to sell counterfeit or substandard products under a legitimate guise. Additionally, illicit online pharmacies may disseminate misleading information about medications, overutilize prescription drugs, and promote medications with questionable safety. Even though these concerns warrant attention from the international community, technology has been beneficial to the pharmaceutical industry by increasing widespread accessibility, saving production costs, and optimizing efficiency of care.[4] It is up to this committee to balance these benefits with the possible consequences of bad faith actors taking advantage of the new vulnerabilities. Nevertheless, this committee's principal priority is to navigate the digitization of the pharmaceutical industry by addressing regulation and management of the market.

History:

In the early 20th century, the development of antitoxins and vaccines sparked the growth of the pharmaceutical sector; up until then, medicines were derived from natural remedies, and there was limited knowledge surrounding infectious diseases and treatments. World War II spurred major advancements in pharmaceutical knowledge by accelerating the large-scale manufacturing and trade of penicillin, cortisone, and other antibacterials. By 1943, US pharmaceutical companies were selling medications globally to treat war-related injuries and diseases such as syphilis and gonorrhea. After the war, the declassification of many scientific advances coupled with increased funding of scientific research led to more landmark discoveries such as the polio vaccine in 1954. In the 1960s, the pharmaceutical industry became more knowledgeable and credible after a surge of drug regulations following public outrage over the promotion of the drug thalidomide; in the late 1950s, thalidomide was widely marketed as a

---

[3] Almeman, Ahmad. "The Digital Transformation in Pharmacy: Embracing Online Platforms and the Cosmeceutical Paradigm Shift," National Library of Medicine, May 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11080122/.

[4] Mackey, Tim and Bryan Liang. "Pharmaceutical Digital Marketing and Governance: Illicit Actors and Challenges to Global Patient Safety and Public Health," National Library of Medicine, October 2013. https://pmc.ncbi.nlm.nih.gov/articles/PMC4016496/.

sedative and treatment for pregnancy-related nausea across Europe, South America, and parts of Asia, despite being linked to severe birth defects. In response, several countries enacted legislation that required medication manufacturers to substantiate claims about the effectiveness and safety of their products; for example, Germany reinforced their 1961 drug safety law to prevent the circulation of thalidomide.[5] The Kefauver-Harris Amendment of 1962 is a US law that required drug manufactures to prove their products are safe and effective before selling them. Similarly, the Medicines Act of 1968 required manufacturers to do the same in the UK.[6]

As the regulation of the industry improved, what is referred to as the "third industrial revolution" of the pharmaceutical industry began. The revolution is characterized by the incorporation and accessibility of computers and digital communication in drug manufacturing and marketing. Technology in manufacturing was used to automate machinery and procedures, which reduced the necessity of manual operators and increased mass production of products. Regarding research, the Advanced Process Analytical Technology (PAT) framework provided quality data of products and manufacturing processes, which increased cost-effectiveness of products and revolutionized product design and research[7].

While the third pharmaceutical industrial revolution is prominent for reducing costs and optimizing efficiency of drug manufacturing, the most recent fourth industrial revolution of the pharmaceutical industry has globalized the industry and normalized automatic and robotic production systems that do not need human oversight. The use of refined automation and artificial intelligence has made the market more flexible to fluctuations in demands and can produce customized products with minimal human intervention; additionally, these advancements can more accurately monitor and analyze production data to continuously optimize production and labor processes. There are five key technologies of the fourth revolution: the Internet of Things, Artificial Intelligence, machine learning, cloud computing, and big data analytics.

---

[5] Cabrera, Diego, Paul Selzer, and Thomas Spangenberg. "A Brief History of the Pharmaceutical Industry," Praziquantel, October 4, 2025. https://link.springer.com/chapter/10.1007/978-3-031-97397-0_1

[6] "Medication Safety Management," NHS England, March 11, 2025. https://www.england.nhs.uk/long-read/medication-safety-management/.

[7] FDA. 2004. "Guidance for Industry PAT -A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance." https://www.fda.gov/media/71012/download.

The Internet of Things (IoT) is "an open wide and informative network of smart devices that can provide information, data, and resources, self-organize, and react and respond in reaction to situations and changes in the environment." The IoT uses real-time monitoring, predictive maintenance, and precise data collection, all of which improves production output, reduces prices, and improves methods of dispensing medications. The IoT is revolutionary to the industry because it uses sensors and smart gadgets--such as wearable biosensors and implantable devices--to monitor the patient's compliance with and adherence to a recommended prescription. This summarizes the interaction between the physician, manufacturer, distributor and consumer, and uses the information to enhance each actor's role in the system. The IoT can also use cloud software to automate inventory and prevent medicine spoilage by tracking storage and management of medications; IoT systems have reduced vaccine spoilage by up to 15% in recent deployments.[8]

Another key technology is Artificial Intelligence (AI). AI has been especially effective in research by accelerating the identification and validation of drugs and helping researchers identify new treatments faster and more accurately. AI is also capable of predicting safety and efficacy of new drugs, reducing costs resources pooled toward clinical trials. Additionally, AI can create personalized treatment plans tailored to individual patient data, which can help physicians accommodate more patients more efficiently.

Machine Learning (ML) is another aspect of the fourth revolution of the pharmaceutical industry. ML uses data and algorithms to make decisions or predictions without being explicitly programmed. A subset of AI, ML focuses on the development of algorithms and statistical models to analyze large datasets and identify patterns to identify new drug targets. It can also predict equipment failures and adjust production schedules. This enables researchers to analyze and extrapolate biological and chemical data more efficiently and accurately, accelerating the research and discovery process.

A fourth technology that augments collaboration and data sharing across the global industry is cloud computing. Cloud-based platforms can share data across organizations, all over

---

[8] Kumari, R. Kusuma, et al. "IoT Integration in Pharmaceuticals: Opportunities, Challenges, and Future Directions," Intelligent Hospital, December 2025. https://www.sciencedirect.com/science/article/pii/S3050837125000232.

the world, which again accelerates new drug discovery and development in a collaborative manner. Additionally, cloud providers typically implement robust security measures, which ensures compliance with regulatory and safety requirements. Overall, cloud computing further globalizes the pharmaceutical industry by making it more collaborate with data sharing and research while still adhering to regulatory standards.

Another key component, Big Data refers to "the vast and complex volume of information that exceeds the capacity of traditional data and processing methods. Big data encompasses large amounts of data at a high speed and with a large variety of analytical techniques and algorithms. In the pharmaceutical industry, big data tracks data from clinical trials, patient records, genomic information, drug interactions, and more to identify drug candidates more efficiently and personalize treatment plans based on patients' characteristics and histories. Compared to the other four technologies previously discussed, big data best provides a holistic and integrative approach to providing care to patients.[9]

This fourth industrial revolution was largely accelerated by the COVID-19 pandemic. According to polls conducted by Global Data, COVID-19 accelerated the digitization of the pharmaceutical industry by more than five years. While the pandemic delated routine treatments, strained healthcare budgets, derailed drug development for non-COVID related diseases, and more, COVID-19 nonetheless pushed the industry to implement various technologies and improve in many ways. Despite the disruptions of the industry caused by the pandemic, COVID-19 caused significant advancements by forcing the pharmaceutical industry to rapidly and urgently improve patient care, cost-effectiveness, transparency, and drug developments—all of which ameliorated with the integration of new technologies.[10]

Analysis:

Naturally, technological advancements have significantly improved the pharmaceutical industry by reducing costs, augmenting efficiency, and spurring scientific discovery. However,

---

[9] Ale, Yogita, et al. "IoT in Revolutionizing the Pharmaceutical Sector: Applications and Challenges," Biomedical and Pharmacology Journal. Accessed August 18, 2026. https://biomedpharmajournal.org/vol18marchspledition/iot-in-revolutionizing-the-pharmaceutical- sector-applications-and-challenges/.

[10] "COVID-19 Accelerated Digital Transformation of the Pharma Industry by Five Years: Poll," Pharmaceutical Technology, March 9, 2021. https://www.pharmaceutical-technology.com/news/covid-19-accelerated-digital-transformation-of-the-pharma-industry-by-five-years-poll/?cf-view

the international community has a responsibility to regulate and manage these advancements to ameliorate related issues and entirely prevent others.

One issue that may arise from full integration of AI in the pharmaceutical industry is health inequality. While some people reap the benefits from access to digital health programs, others in more vulnerable conditions, who often need the medical support more, do not have access to these opportunities. Additionally, issues like illiteracy and lack of access to the Internet further compound the digital divide, for digital health applications are not well-suited for people with limited reading and digital skills. Fortunately, there are several global initiatives striving to make digital health accessible to all global citizens. These initiatives must mutually exchange and jointly apply knowledge to create a more effective global system; this is where this committee is relevant. The three actions needed to link initiatives and achieve digital universal health coverage are the following: combining knowledge and expertise, which would combine actors local and global, both public and private; implementation of knowledge in practice, which should particularly focus on regions deprived of digital care; and building up joint data infrastructure to connect data from different domains and create a widely-accepted holistic approach. It is the duty of the UN, as the major international government, to lead these three steps by facilitating collaboration between actors and initiatives in the pharmaceutical industry.[11]

The UN also can apply digital innovations to ameliorate transitions between care settings. People with long-term medical conditions frequently transition between home and the hospital, which requires transferring information about a patient's medicines between systems. Transitions are often error prone and lead to unintentional changes to medications, which can seriously harm patients; for example, one study conducted in England estimates approximately 250,000 serious medication errors occur when a patient transitions from hospital to home. While the implementation of digital tools to ease transitions is currently handled domestically, UNODC can manage the exchange of research and methods across Member States to ensure all states know how to alleviate transitional errors with new technologies. This committee should also work to

[11] Tensen, Paulien, et al. "Digital Health for All: How Digital Health Could Reduce Inequality and Increase Universal Health Coverage," National Library of Medicine, July 7, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10331232/.

universalize standards globally to encourage homogenous digital standards within states as well.[12]

Even though technological advancements in the pharmaceutical industry present opportunities for improved health care and coverage, new technologies have also created new vulnerability, easily exploitable by bad faith actors. The greatest challenge concerning the digitization of public health is the growing global supply chain of "counterfeit medicines," which are intentionally fraudulent, poor quality unregulated drugs sold under the pretense of being regulated, safe, and effective. These medicines threaten lives, lead to antimicrobial resistance, and fund criminal actors, further encouraging the illicit activity. The industry for counterfeit medicines is estimated between $75 and $200 billion, which reveals how large of an issue this is and suggests the lack of reliable information surrounding the topic. At the moment, surveillance for counterfeit medicines is extremely limited.

While the World Health Organization (WHO) leads the response as the primary international public health agency, the WHO does not possess enforcement capabilities and cannot address specific criminal or law enforcement issues. The WHO, UNODC, and Interpol are already individually engaged in preventing the circulation of counterfeit medicines, but a trilateral mechanism would centralize and optimize these efforts. The UNODC, mandated by the Crime Prevention and Criminal Justice resolution, is empowered to fight against counterfeit medicine circulation by conducting research, providing technical assistance to Member States, and cooperating with other international organizations.

UNDOC resolutions have historically gained broader international support than actions conducted solely by WHO. For examples, Resolution 10/5 and Resolution 20/6 officially categorize the trafficking of fraudulent medicines as a sever transnational organized crime instead of a mere intellectual property of public health issue. Resolution 10/5 urges Member States to investigate and prosecute manufacturers and traffickers of counterfeit medicines through the UN Convention against Transnational Organized Crime (UNTOC). Interpol can mobilize law enforcement, customs and border assets, and develop intervention operations to

[12] Tolley, Clare, et al. "Barriers and Opportunities for the Use of Digital Tools in Medicines Optimization Across the Interfaces of Care: Stakeholder Interviews in the United Kingdom," National Library of Medicine, March 10, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10039399/.

disrupt trafficking—all of which would put research and norms developed by the WHO and UNODC into practice. A trilateral mechanism between the three organizations would be composed of these roles: the UNODC as the official chair and coordinator of efforts to reduce transnational pharmaceutical crime; the WHO as the collector of data and surveillance particularly regarding the impact on global public health; and Interpol as the mobilizer of law enforcement resources and field operations. It is up to the UNODC, as potential chair of this mechanism, to collaborate with the WHO and Interpol and design this mechanism.

Conclusion:

Technological advancements in the pharmaceutical industry are beneficial in reducing costs, optimizing efficiency, and accelerating research and development of new medicines. The IoT, AI, ML, cloud computing, and Big Data have spurred research of new drugs and accelerated the collection and analysis of data related to manufacturing processes. While new technologies have naturally improved the industry, UNODC and other international bodies can harness these technologies to tackle specific issues such as the digital divide and transitional errors.

However, new technologies have resulted in benefits as well as new vulnerabilities that have been exploited by illicit actors to develop and more easily traffic counterfeit medicines. UNODC has already acted through resolutions to combat the circulation of counterfeit medicines, but UNODC must initiate a trilateral mechanism alongside the WHO and Interpol to pool efforts and fill in each organization's unique gaps. This committee must navigate regulation and management of new technologies by working with Member States and international bodies to increase accessibility to digital health care and reduce errors resulting from digitization.

Questions to Consider:

1. How can this committee use new technologies to navigate the digital divide, errors in patient transitions, and other problems?
2. How can the UNODC work with Interpol and the WHO to counter the circulation of counterfeit medicines?
3. How can the UNODC work with other health-focused bodies to mutually exchange information and jointly navigate new technologies?

Bibliography

Ale, Yogita, et al. “IoT in Revolutionizing the Pharmaceutical Sector: Applications and Challenges,” Biomedical and Pharmacology Journal. Accessed August 18, 2026. https://biomedpharmajournal.org/vol18marchspledition/iot-in-revolutionizing-the-pharmaceutical-sector-applications-and-challenges/.

Almeman, Ahmad. “The Digital Transformation in Pharmacy: Embracing Online Platforms and the Cosmeceutical Paradigm Shift,” National Library of Medicine, May 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11080122/.

Cabrera, Diego, Paul Selzer, and Thomas Spangenberg. “A Brief History of the Pharmaceutical Industry,” Praziquantel, October 4, 2025. https://link.springer.com/chapter/10.1007/978-3-031-97397-0_1

“COVID-19 Accelerated Digital Transformation of the Pharma Industry by Five Years: Poll,” Pharmaceutical Technology, March 9, 2021. https://www.pharmaceutical-technology.com/news/covid-19-accelerated- digital-transformation-of-the-pharma-industry-by-five-years-poll/?cf-view

FDA. 2004. “Guidance for Industry PAT -A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance.” https://www.fda.gov/media/71012/download.

Kumari, R. Kusuma, et al. “IoT Integration in Pharmaceuticals: Opportunities, Challenges, and Future Directions,” Intelligent Hospital, December 2025. https://www.sciencedirect.com/science/article/pii/S3050837125000232.

Mackey, Tim and Bryan Liang. “Pharmaceutical Digital Marketing and Governance: Illicit Actors and Challenges to Global Patient Safety and Public Health,” National Library of Medicine, October 2013. https://pmc.ncbi.nlm.nih.gov/articles/PMC4016496/.

“Medication Safety Management,” NHS England, March 11, 2025. https://www.england.nhs.uk/long-read/medication-safety-management/.

NIH. “Pharmaceutical Industry.” National Institute of Health. Accessed August 18, 2026. https://toolkit.ncats.nih.gov/glossary/pharmaceutical-industry/.

Tensen, Paulien, et al. “Digital Health for All: How Digital Health Could Reduce Inequality and Increase Universal Health Coverage,” National Library of Medicine, July 7, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10331232/.

Tolley, Clare, et al. “Barriers and Opportunities for the Use of Digital Tools in Medicines Optimization Across the Interfaces of Care: Stakeholder Interviews in the United Kingdom,” National Library of Medicine, March 10, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10039399/.

UNODC. “UNODC: About Us,” UN Office on Drugs and Crime. Accessed August 17, 2026. https://www.unodc.org/unodc/en/about-unodc/index.html.

Topic II: Alternative Development of Economies Supported by Illicit Drugs

Statement of the Issue:

Many economies across the world are supported by the illicit drug trade, which only exacerbates the world drug problem and deters states from taking real action to stop the trafficking of illicit drugs. By designing supply reduction strategies, empowering local ownership, and reducing dependency on illicit crops, the UNODC is committed to alternative development of economies supported by illicit narcotics. Typically, alternative development entails a shift in agricultural production or land use, so it is important to the UNODC to take environmentally sustainable initiatives. It is this committee's responsibility to assess how alternative development can best be implemented and how to collaborate with other actors to best do so.

History:

The trafficking of illegal drugs dates back to the late 18th century with the British East India Company. The British East India Company, having monopolized opium in 1793, became the world's first drug cartel, predominantly shipping opium to China. In 1839, the First Opium War began when China attempted to stop Britain from illegally smuggling opium from India into Chinese markets; China's loss in the war resulted in "unequal treaties" that allowed foreign powers to dominate China through the opium trade, and the importation of opium was later legalized in China after the Second Opium War or 1856.[13] While opium was largely restricted and banned across states including the US, Britain, China, India, and France, the trade of narcotics flourished into the 20th century. The British and French largely controlled opium production in Southeast Asia until opium trade routes in the region were blocked off during World War II. Following the war, the US and France, in an attempt to prevent the spread of communism in Asia, supplied anticommunist drug warlords and armies with ammunition, arms, and air transport for the production and sale of heroin; the point of this support was to maintain relationships with the warlords to hold influence over Asian states and prevent communist

[13] "The Opening to China Part I: the First Opium War, the United States, and the Treaty of Wangxia, 1839-1844," Office of the Historian. Accessed August 19, 2026. https://history.state.gov/milestones/1830-1860/china-1.

regimes. This resulted in the mass illegal flow of heroin into the United States, which continued to surge during the Vietnam War during which Burma and Laos were used to transport raw opium.

While dominant powers such as the US, Great Britain, and France facilitated the illicit narcotics trade, many economies in Southeast Asia, and Latin and South America became dependent on the illicit trade. This paper will discuss three major examples of economies supported by illicit drugs, especially narcotics, to show how and why economies became dependent.

The case of Colombia as a narco-state, which refers to countries where all legitimate institutions become penetrated by the power and wealth of the illegal drug trade, is most well-known because of Pablo Escobar's Medellin cartel which trafficked cocaine into the US in the 1980s. However, Colombia's involvement in the international drug trade originated as a marijuana economy. In the 1970s, Colombian peasants shifted from banana, cotton, and coffee production to marijuana cultivation. While trading products like bananas, coffee, and cotton made some rural farmers rich, the impoverished farmers, who did not benefit from the trade as much, took the opportunity to export illegal marijuana to the US. This again shifted to growing coca leaf for cocaine production when the Colombian and US governments launched a joint anti-marijuana campaign in 1978.[14] Using the profits from marijuana, drug cartels switched to cocaine trafficking; the most prominent Colombian drug cartel is the Medellín Cartel led by Pablo Escobar. Dominating the cocaine trade in the 1980s, the Medellín Cartel earned approximately $420 million a week at its peak.[15] These earnings not only benefited the cartel but supported the Colombian national economy. In 2023, Colombia's cocaine trade poured $15.3 billion into the national economy, which exceeded the $11.8 billion made legally. Coca fields in

[14] Abrams, Joel. "Marijauna Fueled Colombian Drug Trade Before Cocaine Was King," The Conversation, August 4, 2020. https://theconversation.com/marijuana-fueled-colombian-drug-trade-before-cocaine-was-king-142152.

[15] McGreevey, William Paul. "The Growth of Drug Trafficking and Guerrilla Warfare," Britannica, August 19, 2026. https://www.britannica.com/place/Colombia/The-growth-of-drug-trafficking-and-guerrilla-warfare.

Colombia also expanded by 10% in 2023 to increase cocaine output and generate more revenue for the national economy.[16]

Afghanistan is another country with a national economy supported by illicit drugs. The country was the world's leading illicit drug producer from 2001 until 2024 with the industry mainly selling opium. Afghanistan first started producing opium in the mid-1950s to supply Iran after Iran banned poppy cultivation, which is necessary to producing opium. When the Soviets invaded Afghanistan in 1979, opium production ramped up again to finance resistance efforts, and by 1984, Afghanistan supplied 60% of the US cocaine market and 80% of Europe's. When the Taliban took control in 1996, the Taliban strived to stop the circulation of opium and greater illicit drug trade. Former Taliban supreme leader Mullah Mohammed Omar called on the UN to aid in drug eradication in Afghanistan, and in 2000, the UN Security Council adopted Resolution 1333 which helped to eliminate illicit cultivation of opium poppies in addition to further condemning and constraining the Taliban's actions.[17] However, when the Taliban was overthrown in 2001, the groundwork to eradicate the opium trade was in upheaval, and cultivation of opium resumed.

By 2005, Afghanistan was producing 90% of the world's opium, and the UNODC estimates that 52% of the nation's GDP was generated by the drug trade.[18] Afghanistan's high production of opium until the Taliban regained control in 2021 and placed a nationwide ban of opium poppy cultivation in 2022. The ban caused opium cultivation to drop far below the 232,200 hectares recorded before the ban, and it continues to drop from 12,800 hectares in 2024 to 10,200 hectares in 2025. However, inappropriate alternative efforts have left over 40% of farmland barren and have increased economic hardship for those who relied significantly on the illicit drug trade. As opposed to opium, synthetic drug production, particularly methamphetamine, increased by 50% between 2024 and 2025 because synthetic drugs are easier to produce and harder to detect while trafficking for reasons including their complex and flexible

---

[16] Martinez, Sofia Gabriela. "In Colombia Drug Profits Now Rival Legal Foreign Currency Flows," The Rio Times, September 22, 2025. https://www.riotimesonline.com/in-colombia-drug-profits-now-rival-legal- foreign-currency-flows/.

[17] "Resolution 1333 (2000)," UNSC Resolutions. Accessed August 20, 2026. https://unscr.com/en/resolutions/1333/.

[18] "Opium Production in Afghanistan," Wikipedia. Accessed August 20, 2026. https://en.wikipedia.org/wiki/Opium_production_in_Afghanistan.

formulas, which often overlap with ingredients found in legal commercial and industrial pharmaceutical manufacturing.[19]

After the Taliban's ban on poppy cultivation in Afghanistan, which led to a 95% decline in opium farming, Myanmar filled the gap in the global poppy supply. Myanmar is now the world's leading producer of opium with poppy crops accounting for almost a third of Myanmar's agricultural production in 2023. When the military seized power in 2021, the legal economy had already been decimated by conflict and instability, and the military coup only exacerbated issues and drove farmers to grow poppy as a quick and easy way to turn a profit.[20] The military coup resulted in an estimated 18% increase in cultivation. Increases in poppy farming have increased the most in the Shan state, which is part of the Golden Triangle—a notorious hub for drug production and trafficking since the Second Opium War. Shan is a poor and remote region, and many people relocate to Shan for opium farming after losing jobs elsewhere in Myanmar. The UN has suggested alternative development methods to replace poppy with other crops, but the limited resources and economic dependency on the opium market would hinder these efforts.[21]

Analysis:

In 1998, the UNODC adopted the mission "alternative development," which refers to "a process to prevent and eliminate the illicit cultivation of plants containing narcotic drugs and psychotropic substances through specifically designed rural development measures." Alternative development can include narrow crop substitution efforts as well as integrated rural development initiatives.[22] The first UN-led comprehensive crop substitution project was in Lebanon, 1966; this project entailed eradicating illegal cannabis crops and instead subsidizing sunflower seeds as a substitute. Crop substitution projects continued throughout the century in Thailand, Pakistan, Peru, and more. In the 1980s, the UNODC's strategy shifted from crop substitution projects to income substitution and integrated rural development initiatives which focus on infrastructure

---

[19] UN. "Afghanistan: Opium Cultivation Drops Sharply, But Regional Trafficking Rises," UN News, November 6, 2025. https://news.un.org/en/story/2025/11/1166286.

[20] France-Presse, Agence. "Myanmar Becomes World's Biggest Producer of Opium Overtaking Afghanistan," The Guardian, December 12, 2023. https://www.theguardian.com/world/2023/dec/12/myanmar- opium-biggest-producer-overtaking-afghanistan-unodc-study.

[21] Luong, Hai. "How Myanmar Became the Opium Capital of the World," East Asia Forum, May 17, 2024. https://eastasiaforum.org/2024/05/16/how-myanmar-became-the-opium-capital-of-the-world/.

[22] UNODC. "About Us: Alternative Development," UN Office on Drugs and Crime. Accessed August 20, 2026. https://www.unodc.org/unodc/en/alternative-development/about-us.html.

and the quality of life for locals. Finally, in the 2000s, alternative development was officially embedded in the Millenium Development Goals, which institutionalized the mission within the UN. Alternative development has a long history, but it still faces challenges in implementation and execution.[23]

To ensure successful transitions in alternative development, there are three success factors the UNODC must consider when managing products. First, participants of alternative development projects should receive fair prices and incomes, especially for shifting to an environmentally friendly approach; without economic incentive, the sustainability aspect of alternative development may not be achieved. Second, participants need financial and technical support to navigate the transition; the UNODC should be responsible for providing this support because many of these participants are already in economically unstable positions. Third, while alternative development should integrate sustainable strategies, these programs must promote and protect human rights. Human rights are important in communities where alternative development is necessary because impoverished farmers who turn to illicit drug cultivation are often undervalued and neglected by governmental authorities, which is an initial factor of their economic despair. In Colombia, several alternative development projects have incorporated all three success factors. For example, the UNODC has allocated land to participants to protect and care for the environment while empowering participants with the designation of land use rights.

Alternative development programs still face many challenges. One problem stems from alternative development having two goals: to reduce illicit crop production and to promote sustainable rural development. This committee should assess how to balance those two goals especially when weighting one greater than the other can be detrimental to the execution of the program. For instance, focusing on sustainability too much can prevent and even disincentivize participants from benefiting from an alternative development program. One of the success factors discussed earlier is fair income and prices to incentivize participants to ensure sustainable practices, but without resources to economically incentivize participants, sustainability may be

[23] UNODC. “Practical Guide of Alternative Development and the Environment: Introduction,” UN Office on Drugs and Crime, October 2023. https://www.unodc.org/documents/alternative-development/Practical_Guide_Report_web.pdf.

foregone to prioritize the people. The question this committee faces is how to balance those two prioritizes.

Another challenge with alternative development programs revolves around collective action. When there are several interventions managed by different agencies guided by different mandates, there can be points of contradiction and friction that lead to gridlock. The UNODC, as the dominant international body committed to alternative development, must develop standardized programs and regulations for these agencies to follow to ensure all actors are on the same page. Otherwise, the possible benefits of alternative development programs will be nullified.

A third problem that may arise with alternative development is exclusionary programs. Typically, alternative development focuses on landowners; this means that the landless, land poor, women, youth, and other marginalized groups may be neglected and fall into even more drastic economic despair. While alternative development attempts to relieve economic inequality, programs can widen the disparity by benefiting landowners, albeit impoverished, over more marginalized groups. It is this committee's responsibility to target marginalized groups as much as landowners in an effort to not exacerbate economic disparity.

Conclusion:

Many economies, including those of Colombia, Afghanistan, and Myanmar, are fueled by the global illicit drug trade, and domestic action may not be enough to help cultivators profit from other means. Thus, the UNODC and the greater international community are necessary actors in helping these economies transition. Alternative development is a valuable method to help economies supported by illicit drugs transition to legal means of currency; it can look like crop substitution programs or land use initiatives, and the method seeks to use sustainable projects to relieve farmers of dependency on drug production.

While alternative development can be effective, it faces problems like balancing sustainability with reduction of illicit crop production, and navigating gridlock caused by multiple independent actors. Programs can also neglect marginalized groups by solely aiding landowners. It is this committee's responsibility to counter these problems to optimize effectiveness of alternative development while promoting its values.

Questions to consider:

1. How should the two goals of sustainability and reduction of illicit crop production be weighted in alternative development programs?
2. How can the UNODC use alternative development programs to empower landowners and marginalized groups to be independent from profiting from the illicit drug industry?
3. How should the UNODC rally other independent organizations to jointly implement alternative development projects? Or how should this committee create norms and standards to prevent gridlock stemming from several independent actors?

Bibliography

Abrams, Joel. "Marijauna Fueled Colombian Drug Trade Before Cocaine Was King," The Conversation, August 4, 2020. https://theconversation.com/marijuana-fueled-colombian-drug-trade-before-cocaine-was-king-142152.

France-Presse, Agence. "Myanmar Becomes World's Biggest Producer of Opium Overtaking Afghanistan," The Guardian, December 12, 2023. https://www.theguardian.com/world/2023/dec/12/myanmar-opium-biggest-producer-overtaking-afghanistan-unodc-study.

Luong, Hai. "How Myanmar Became the Opium Capital of the World," East Asia Forum, May 17, 2024. https://eastasiaforum.org/2024/05/16/how-myanmar-became-the-opium-capital-of-the-world/.

Martinez, Sofia Gabriela. "In Colombia Drug Profits Now Rival Legal Foreign Currency Flows," The Rio Times, September 22, 2025. https://www.riotimesonline.com/in-colombia-drug-profits-now-rival-legal-foreign-currency-flows/.

McGreevey, William Paul. "The Growth of Drug Trafficking and Guerrilla Warfare," Britannica, August 19, 2026. https://www.britannica.com/place/Colombia/The-growth-of-drug-trafficking-and-guerrilla-warfare.

"Opium Production in Afghanistan," Wikipedia. Accessed August 20, 2026. https://en.wikipedia.org/wiki/Opium_production_in_Afghanistan.

"Resolution 1333 (2000)," UNSC Resolutions. Accessed August 20, 2026. https://unscr.com/en/resolutions/1333/.

"The Opening to China Part I: the First Opium War, the United States, and the Treaty of Wangxia, 1839-1844," Office of the Historian. Accessed August 19, 2026. https://history.state.gov/milestones/1830-1860/china-1.

UN. "Afghanistan: Opium Cultivation Drops Sharply, But Regional Trafficking Rises," UN News, November 6, 2025. https://news.un.org/en/story/2025/11/1166286.

UNODC. "About Us: Alternative Development," UN Office on Drugs and Crime. Accessed August 20, 2026. https://www.unodc.org/unodc/en/alternative-development/about-us.html.

UNODC. “Practical Guide of Alternative Development and the Environment: Introduction,” UN Office on Drugs and Crime, October 2023. https://www.unodc.org/documents/alternative-development/Practical_Guide_Report_web.pdf.